Aptamers Engineered Nanocarriers for Cancer Therapy

Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.

1. Cell-SELEX technology for aptamer selection
2. Biological characteristics of aptamers
3. Mechanisms of multi-drug resistance of cancer
4. Relevance of aptamers as targeting ligands for anticancer therapies
5. Aptamers as smart ligands for nano-carriers cancer targeting
6. Aptamer-functionalized liposomes for targeted cancer therapy
7. Aptamer-functionalized micelles for targeted cancer therapy
8. Aptamer-functionalized nanoparticles for targeted cancer therapy
9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy
10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy
11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy
12. Aptamer-functionalized dendrimers for targeted cancer therapy
13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy
14. Aptamer-functionalized quantum dots for targeted cancer therapy
15. Cancer immunotherapy via nucleic acid aptamers
16. Aptamer-based imaging and diagnostics for cancer cells
17. Microdevice-based aptamer sensors
18. Aptamer-based microfluidics for circulating tumor cells
19. Aptamer-based theranostic approaches for treatment of cancer
20. Challenges of aptamers as targeting ligands for anticancer therapies
21. Clinical use and future perspective of aptamers